Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
ALLO
$15.81
Allogene Therapeutics
($.77)
(4.64%)
ALLO
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus: ($0.64)
Revenue: $0.01 Mil
Tuesday
Nov 8
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Tuesday, August 09, 2022
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
What do you expect when ALLO reports earnings?
Beat
Meet
Miss
Where is ALLO's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$17.31
$16.92
$16.37
$15.98
Support
$15.42
$15.03
$14.48
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical stage. Allogene Therapeutics, Inc. is headquartered in South San Francisco, California.
Expectations
›
Allogene Therapeutics
